Johnson & Johnson (NYSE:JNJ) subsidiary LifeScan said today it inked a strategic collaboration deal with WellDoc Corporation and joined in a Series B round of financing for the company, with goals of advancing mobile solutions for Type 2 diabetes patients.
Through the collaborative deal, the companies said they will seek to integrate LifeScan’s OneTouch Verio Flex blood glucose monitoring system and OneTouch Reveal Mobile application with WellDoc’s BlueStar diabetes management platform and mobile app, which has FDA approval for treating type 2 diabetes, LifeScan said.
“We are continuously working to empower diabetes patients by developing and integrating innovative technologies that can improve both daily experiences and long-term health. This exciting collaboration bridges our strong history serving diabetes patients and their healthcare team with WellDoc’s innovative diabetes management platform that has been shown to improve health outcomes. By working together, we look forward to advancing new solutions,” LifeScan worldwide prez Val Asbury said in a prepared statement.
The integration of the systems is intended to provide patients with smart monitoring tools and motivational, behavioral and educational coaching that LifeScan claims has been shown to improve patient health.
LifeScan said that in a clinical trial of WellDoc’s platform, patients who used the system showed a 1.9% decrease in glycated hemoglobin level over 12 months, 1.2% higher than the “usual care” group.
In January, Johnson & Johnson’sAnimas Corporation subsidiary said the FDA approved its Animas Vibe insulin pump and continuous glucose monitoring system for children and adolescents ages 2 to 17.
The Animas system allows patients and caregivers to access and view glucose data and administer insulin through the pump remotely to allow for more careful management of diabetes, the company said.